RxDoctor Payments DataLook up a doctor →

Fadi Joudi, MD

Urology · Wichita, KSNPI 1427050079

Payments from drug & device makers

$2,278,215in general payments, 2019–2025

Across 747 payments — averaging $3049.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$1.2M
  • Pfizer$870K
  • Dendreon Pharmaceuticals LLC$177K
  • Urogen Pharma, Inc.$38K
  • Sumitomo Pharma America, Inc.$22K
  • Daiichi Sankyo Inc.$1K
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$4,09834%
  • Speaking & faculty fees$1,1109%
  • Food & beverage$6,43554%
  • Education$3353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,278,215 in reported general payments places this provider in the 95th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$745,267
Medicare patients
1,900
Services billed
29,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide70$1,024,481
XtandiEnzalutamide58$822,050
NubeqaDarolutamide49$646,248
OrgovyxRelugolix193$510,188
GemtesaVibegron249$132,446
Abiraterone Acetate36$86,127
MyrbetriqMirabegron125$66,822
Solifenacin Succinate301$11,469
Tamsulosin Hcl787$7,442
Potassium Citrate ErPotassium Citrate33$2,947
Finasteride281$2,448
Cephalexin388$1,995
Estradiol26$1,991
Fesoterodine Fumarate ErFesoterodine Fumarate20$1,892
Methenamine Hippurate41$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$668$1,024,48170 claims
Astellas Pharma US IncXtandi, Myrbetriq$317$888,871183 claims
BayerNubeqa$989$646,24849 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$21,533$642,633442 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$97$86,12736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 urology providers in Kansas.

Other urology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →